Inspira Appoints Former Johnson & Johnson Executive as VP of Global Sales and New Board Member from a Leading International Investment Firm
Inspira (NASDAQ: IINN) announced two leadership appointments on October 21, 2025: Mike Hershkovitz as Vice President of Global Sales and Sivan Matza as an independent member of the board of directors. Ms. Matza will join the compensation, audit and financial statement examination committees and succeeds Limor Rosen, who is stepping down.
Ms. Matza oversees tens of billions of dollars in assets at a leading international investment firm and brings experience in global finance, regulation and accounting. Mr. Hershkovitz brings nearly two decades of commercial leadership, including senior roles at Johnson & Johnson, to lead Inspira’s sales strategy and hospital adoption initiatives worldwide.
Inspira (NASDAQ: IINN) ha annunciato due nomine dirigenziali il 21 ottobre 2025: Mike Hershkovitz come Vice President Global Sales e Sivan Matza come membro indipendente del consiglio di amministrazione. La signora Matza entrerà a far parte dei comitati compensi, audit e esame dei rendiconti finanziari e sostituisce Limor Rosen, che si sta dimettendo.
La signora Matza gestisce asset per decine di miliardi di dollari presso una primaria società internazionale di investimenti e porta con sé esperienza in finanza globale, regolamentazione e contabilità. Il signor Hershkovitz vanta quasi due decenni di leadership commerciale, tra cui ruoli di alto livello presso Johnson & Johnson, per guidare la strategia di vendita di Inspira e le iniziative di adozione ospedaliera in tutto il mondo.
Inspira (NASDAQ: IINN) anunció dos nombramientos de liderazgo el 21 de octubre de 2025: Mike Hershkovitz como Vicepresidente de Ventas Globales y Sivan Matza como miembro independiente del consejo de administración. La Sra. Matza se unirá a los comités de compensación, auditoría y revisión de estados finances y sucede a Limor Rosen, que dimite.
La Sra. Matza supervisa decenas de miles de millones de dólares en activos en una firma de inversión internacional líder y aporta experiencia en finanzas globales, regulación y contabilidad. El Sr. Hershkovitz aporta casi dos décadas de liderazgo comercial, incluyendo roles sénior en Johnson & Johnson, para liderar la estrategia de ventas de Inspira y las iniciativas de adopción por parte de hospitales a nivel mundial.
Inspira (NASDAQ: IINN)은 2025년 10월 21일에 두 명의 리더십 선임을 발표했습니다: Mike Hershkovitz를 글로벌 세일즈 부사장으로, Sivan Matza를 이사회 독립 위원으로 임명합니다. 마즈아 부인은 보수, 감사 및 재무제표 감사 위원회에 합류하며 물러나는 Limor Rosen의 자리를 대체합니다.
마즈아 부인은 글로벌 투자 firm의 자산을 수십억 달러 규모로 관리하며 글로벌 금융, 규제, 회계 분야의 경험을 제공합니다. Hershkovitz 씨는 Johnson & Johnson에서의 고위직을 포함하여 거의 20년의 상업 리더십을 보유하고 있으며 Inspira의 글로벌 판매 전략과 병원 채택 이니셔티브를 이끌 것입니다.
Inspira (NASDAQ: IINN) a annoncé deux nominations de leadership le 21 octobre 2025: Mike Hershkovitz en tant que Vice-président des Ventes Globales et Sivan Matza comme membre indépendant du conseil d'administration. Mme Matza rejoindra les comités de rémunération, d'audit et d'examen des états financiers et succède à Limor Rosen, qui se retire.
Mme Matza supervise des dizaines de milliards de dollars d'actifs dans une grande société d'investissement internationale et apporte une expérience en finance mondiale, réglementation et comptabilité. M. Hershkovitz apporte près de deux décennies de leadership commercial, y compris des postes de direction chez Johnson & Johnson, pour diriger la stratégie de vente d'Inspira et les initiatives d'adoption par les hôpitaux dans le monde.
Inspira (NASDAQ: IINN) gab am 21. Oktober 2025 zwei Führungspositionen bekannt: Mike Hershkovitz als Vice President Global Sales und Sivan Matza als unabhängiges Mitglied des Board of Directors. Frau Matza wird den Komitees Vergütung, Prüfung und Prüfung des Jahresabschlusses beitreten und Limor Rosen ablösen, die zurücktritt.
Frau Matza beaufsichtigt Vermögenswerte in Höhe von mehreren Jahrzehntausenden Milliarden Dollar bei einem führenden internationalen Investmentunternehmen und bringt Erfahrung in globaler Finanzen, Regulierung und Buchführung mit. Herr Hershkovitz verfügt über fast zwei Jahrzehnte Führungserfahrung im kommerziellen Bereich, darunter leitende Positionen bei Johnson & Johnson, um Inspiras Vertriebsstrategie und Hospital-Adoptionsinitiativen weltweit zu lenken.
Inspira (NASDAQ: IINN) أعلنت عن تعيينين قياديين في 21 أكتوبر 2025: مايك هيرشكوفيتز كنائب رئيس للمبيعات العالمية وسيفان ماتزا كعضو مستقل في مجلس الإدارة. ستنضم السيدة ماتزا إلى لجان التعويض والتدقيق ومراجعة البيانات المالية وتحل محل ليومور روزن التي ستتخلى عن منصبها.
تشرف السيدة ماتزا على عشرات مليارات الدولارات من الأصول في شركة استثمارية دولية رائدة وتقدم خبرة في التمويل العالمي والتنظيم والمحاسبة. يجلب السيد هيرشكوفيتز ما يقرب من عقدين من القيادة التجارية، بما في ذلك مناصب عليا في Johnson & Johnson، لقيادة استراتيجية مبيعات Inspira ومبادرات اعتماد المستشفيات حول العالم.
Inspira (NASDAQ: IINN) 宣布在 2025年10月21日 任命了两位领导层： Mike Hershkovitz 为全球销售副总裁，Sivan Matza 为董事会独立成员。Matza 女士将加入薪酬、审计和财务报表审查委员会，并接替下台的 Limor Rosen。
Matza 女士在一家国际领先的投资公司管理着数十亿美元的资产，具备全球金融、监管和会计方面的经验。Hershkovitz 先生拥有近二十年的商业领导经验，其中包括在强生公司的高层任职，将领导 Inspira 的全球销售策略和医院采纳计划。
- None.
- None.
RA'ANANA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced two key leadership appointments that reinforce its global commercialization and governance – the appointment of Mr. Mike Hershkovitz as Vice President of Global Sales of the Company and the appointment of Ms. Sivan Matza as a member of the board of directors of the Company (the “Board”). The Board appointed Ms. Matza to serve as an independent director of the Company until the next annual general meeting of the Company’s shareholders. Ms. Matza will also serve as a member of the Board’s compensation committee, audit committee and financial statement examination committee. Ms. Matza will succeed Ms. Limor Rosen, who is stepping down from the Board.
Ms. Sivan Matza is a Director at a leading international investment management firm overseeing tens of billions of dollars in assets. Her extensive experience in global finance, regulation and accounting strengthens Inspira’s governance framework as the Company accelerates its commercial expansion.
Mr. Mike Hershkovitz, based in the United States, has been appointed Vice President of Global Sales. Mr. Hershkovitz brings nearly two decades of leadership in U.S. and international healthcare markets, including senior commercial roles at Johnson & Johnson and other global med-tech organizations. He will lead Inspira’s sales strategy and hospital adoption initiatives worldwide.
Dagi Ben-Noon, CEO of Inspira Technologies, commented: “The addition of Sivan and Mike to our leadership team is a strategic step that meaningfully enhances Inspira’s capabilities. Sivan’s experience in international finance and regulation from a top-tier firm is an invaluable asset as we expand our operations and strengthen our governance.
In parallel, Mike’s proven leadership in sales and commercial management, including his tenure at Johnson & Johnson, together with his strong understanding of the med-tech industry, will drive our commercial strategy and speed the adoption of our technologies in hospitals worldwide. Their combined expertise is a powerful catalyst for Inspira’s next phase of growth and execution.”
The Company also extended its appreciation to Ms. Limor Rosen, who is stepping down from the Board of Directors.
"We thank Limor for her contribution and commitment to Inspira’s vision and wish her continued success and welcome Sivan to the Board,” stated Tal Parnes, chairman of the Board.
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s U.S. Food and Drug Administration -cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. The Company’s recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the reinforcement of its global commercialization and governance following the new appointments, the strengthening of the Company’s governance framework as the Company accelerates its commercial expansion, the potential of the appointments in leading the Company’s commercial strategy and acceleration of its technology’s adoption in hospitals and the combined expertise serving as a powerful catalyst that will bolster the Company as it enters its next phase of accelerated growth and execution. These forward-looking statements and their implications are based solely on the current expectations of the Company’s management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC’s website at www.sec.gov.
Company Contact
Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485
FAQ
Who did Inspira (IINN) appoint to its board on October 21, 2025?
What role was Mike Hershkovitz given at Inspira (IINN) on October 21, 2025?
Which board committees will Sivan Matza serve on at Inspira (IINN)?
Who is leaving the Inspira (IINN) board following the October 21, 2025 appointments?
What relevant experience do the new Inspira (IINN) hires bring for commercialization?
